哮喘、慢阻肺与SARS-CoV-2感染(COVID-19):潜在机制探讨
本文为致编辑的信,讨论哮喘患者相比慢阻肺患者对COVID-19并发症似乎有一定保护现象,可能与病毒附着蛋白变异、吸入糖皮质激素使用、吸烟/电子烟状态、偏斜的炎症模式及内吞机制失调有关。作者指出观察性研究无法提供因果证据,需进一步理解SARS-CoV-2感染易感性的机制。
要点
- 哮喘患者COVID-19并发症风险似乎低于慢阻肺患者。
- 潜在机制包括病毒附着蛋白变异、ICS使用、吸烟状态等。
- 观察性研究无法提供因果证据,需机制研究。
核心结论
- 哮喘患者相比慢阻肺患者对COVID-19并发症似乎有一定保护,但观察性研究无法提供因果证据。
主要发现
- 哮喘患者对COVID-19并发症似乎有一定保护,而吸烟或慢阻肺患者风险更高。
- 潜在机制包括病毒附着蛋白变异、ICS使用、吸烟/电子烟状态、偏斜的炎症模式及内吞机制失调。
局限性
- 观察性研究无法提供 cause and effect 证据。
- 需进一步理解SARS-CoV-2感染易感性的机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with asthma are somewhat protected from COVID-19 complications compared to COPD. This may be due to variability in viral attachment protein, ICS use, smoking/vaping status, a skewed inflammatory pattern, and dysregulated endocytic machinery. https://bit.ly/3qOcyNb We read with interest the manuscripts [1, 2] and the accompanying editorial [3] describing the risk of severe disease and infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and asthma, but are struck by the difference seen with risk of complications from asthma and coronavirus disease 2019 (COVID-19) compared to the experience during the 2009 influenza pandemic, where people with asthma were clearly at heightened risk, at least of hospitalisation [4]. In contrast, those who smoke or have COPD, appear at greater risk. Observational studies will never be able to provide evidence of cause and effect and a greater understanding of the mechanisms of susceptibility to infection with SARS-CoV-2 is also required. Hence, we would like to take this further and enhance discussion on potential mechanisms (figure 1).
引用
- Wark PAB, Pathinayake PS, Eapen MS, et al. Asthma, COPD and SARS-CoV-2 infection (COVID-19): potential mechanistic insights. Eur Respir J. 2021. PMID: 34244320. doi:10.1183/13993003.00920-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。